2016•Journal watchRequires access

Warfarin vs. Apixaban in Atrial Fibrillation Patients Who Receive Multiple Drugs

Paul S. Mueller, FACP. FACP.

Abstract

Polypharmacy can affect the safety and efficacy of warfarin, given the many known interactions between warfarin and other drugs. However, the effect of polypharmacy on outcomes with direct oral anticoagulants is unclear. In the ARISTOTLE randomized trial, in which 18,000 people with atrial fibrillation (AF) received apixaban (Eliquis) or warfarin, apixaban was superior to warfarin in preventing stroke or systemic embolism and major bleeding and was associated with …

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Apixaban, Warfarin, Medicine, Atrial fibrillation, Polypharmacy, Stroke (engine), Rivaroxaban, Randomized controlled trial